Biopharm we have the "holy grail" bavituximab will help ALL patients with cancer. If used upon diagnosis in all cancers there is a strong chance a healthy immune system could cure the patient.
Bavituximab will be soc initial therapy for all patients with cancer in five years then the practitioner will prescribe the best cocktail ctl4 pd1 chemo radiation etc if the immune system is not enough.
Hard to believe when we're sitting at 1.30/share?
Markets have a way of correcting themselves. Correction coming in 2015 imo, next week next month?
News 
Market Data 
Discover 
